Alpha Healthcare Acquisition Corp. (AHAC)
Price:
10.96 USD
( + 0.81 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Churchill Capital Corp X
VALUE SCORE:
7
2nd position
M3-Brigade Acquisition V Corp. Units
VALUE SCORE:
11
The best
Horizon Kinetics SPAC Active ETF
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Alpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
NEWS
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.
globenewswire.com
2021-08-26 16:05:00DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the successful completion of its business combination (the “Business Combination”) with Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company sponsored by Constellation Alpha Holdings. The resulting combined company, Humacyte, is expected to commence trading of its shares of common stock and warrants on the Nasdaq Global Select Market® under the ticker symbols "HUMA" and “HUMAW,” respectively, on August 27, 2021. The Business Combination was approved by AHAC stockholders on August 24, 2021.
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination
globenewswire.com
2021-08-04 16:53:00NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") and set a date of August 24, 2021, for its special shareholder meeting (the “Special Meeting”) to vote on, among other items, the proposed business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale.
EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack'
benzinga.com
2021-05-25 15:35:53Humacyte is set to go public via the special purpose acquisition company Alpha Healthcare Acquisition Corp (NASDAQ: AHAC) in a deal that values the company at around $800 million. Humacyte founder and CEO Laura Niklason and Alpha Healthcare Acquisition CEO Rajiv Shukla appeared on Benzinga's YouTube show "SPACs Attack" for an exclusive interview Tuesday.
2 SPAC Stocks That Could Be 10-Baggers
fool.com
2021-03-14 06:05:00They could even deliver greater gains than just a 10-times return.
Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021
globenewswire.com
2021-03-05 07:30:00DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in hemodialysis have been accepted for oral presentation at the Charing Cross (CX) International Symposium taking place virtually April 19-22, 2021. On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.
Humacyte: Disrupting The Organ Transplant Industry
seekingalpha.com
2021-02-26 10:10:00Humacyte has a platform technology allowing for the mass production of human organs and blood vessels within a laboratory. Its products are superior as they can be stored for over a year, pose little to no infection risk, and will not be rejected by the immune system.
Regenerative Tissue Developer Humacyte Going Public Via SPAC
fool.com
2021-02-17 13:49:00Humacyte is a leader in regenerative medicine, growing human tissue in the lab that can be transplanted into any patient.
No data to display
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.
globenewswire.com
2021-08-26 16:05:00DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the successful completion of its business combination (the “Business Combination”) with Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company sponsored by Constellation Alpha Holdings. The resulting combined company, Humacyte, is expected to commence trading of its shares of common stock and warrants on the Nasdaq Global Select Market® under the ticker symbols "HUMA" and “HUMAW,” respectively, on August 27, 2021. The Business Combination was approved by AHAC stockholders on August 24, 2021.
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination
globenewswire.com
2021-08-04 16:53:00NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") and set a date of August 24, 2021, for its special shareholder meeting (the “Special Meeting”) to vote on, among other items, the proposed business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale.
EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack'
benzinga.com
2021-05-25 15:35:53Humacyte is set to go public via the special purpose acquisition company Alpha Healthcare Acquisition Corp (NASDAQ: AHAC) in a deal that values the company at around $800 million. Humacyte founder and CEO Laura Niklason and Alpha Healthcare Acquisition CEO Rajiv Shukla appeared on Benzinga's YouTube show "SPACs Attack" for an exclusive interview Tuesday.
2 SPAC Stocks That Could Be 10-Baggers
fool.com
2021-03-14 06:05:00They could even deliver greater gains than just a 10-times return.
Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021
globenewswire.com
2021-03-05 07:30:00DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in hemodialysis have been accepted for oral presentation at the Charing Cross (CX) International Symposium taking place virtually April 19-22, 2021. On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.
Humacyte: Disrupting The Organ Transplant Industry
seekingalpha.com
2021-02-26 10:10:00Humacyte has a platform technology allowing for the mass production of human organs and blood vessels within a laboratory. Its products are superior as they can be stored for over a year, pose little to no infection risk, and will not be rejected by the immune system.
Regenerative Tissue Developer Humacyte Going Public Via SPAC
fool.com
2021-02-17 13:49:00Humacyte is a leader in regenerative medicine, growing human tissue in the lab that can be transplanted into any patient.